Unforeseen off-target effects in clinical drug trials represent a growing expense in drug development. Biomimetic preclinical models that capture these off-target effects before human trials can maximally reduce these development costs, particularly for cardiotoxicity testing. As preclinical models, lab-grown organoids offer extremely high physiological accuracy yet exhibit high variance and complicated setup. To modulate cardiac organoid activities toward facilitating their development, this thesis developed induced-pluripotent stem cell cardiomyocyte (iPSC-CM) organoids and uses fiber optoacoustic emitters (FOEs) to photoacoustically stimulate cardiomyocyte organoids. As a platform for developing preclinical cardiac models, high-precision photoacoustic control offers a tunable, non-invasive system that offers insights into cell therapies and biomaterials to improve long-term patient outcomes.
| Identifer | oai:union.ndltd.org:bu.edu/oai:open.bu.edu:2144/48882 |
| Date | 24 May 2024 |
| Creators | Sharma, Vikrant |
| Contributors | Yang, Chen |
| Source Sets | Boston University |
| Language | en_US |
| Detected Language | English |
| Type | Thesis/Dissertation |
| Rights | Attribution-NonCommercial-NoDerivatives 4.0 International, http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Page generated in 0.0018 seconds